Reserpine Tablets

1Reserpine is an adrenergic neuron blocking antihypertensive drug. 2This product achieves its antihypertensive, heart rate slowing and central nervous system inhibition effects by depleting adrenaline in peripheral sympathetic nerve endings, catecholamines and 5-hydroxytryptamine in the heart, brain and other tissues. The antihypertensive effect is mainly achieved by reducing cardiac output, reducing peripheral resistance, and partially inhibiting cardiovascular reflexes. The effect of slowing the heart rate is not obvious in people with normal heart rate, but it is obvious in people with sinus tachycardia. 3Reserpine acts on the hypothalamus to produce a sedative effect, but does not cause drowsiness or anesthetic effects, does not change the electroencephalogram during sleep, and can relieve anxiety, tension and headaches in hypertensive patients. 4The experimental animals were given

The main ingredient and chemical name of this product are: 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohen-16-carboxylic acid methyl ester

This product is a light yellow tablet or sugar-coated tablet with colorant added, which appears white or light yellowish brown after removing the sugar coating.

Hypertension (not recommended as first-line medication).

Oral administration: initial dose 0.1-0.25 mg/time, once daily. After a dose adjustment period of 7-14 days, the maintenance dose is determined by the minimum effective dose; the maximum dose should not exceed 0.5 mg/time. Reserpine is usually used in combination with thiazide diuretics to reduce the dose and adverse reactions. Children are given 0.005-0.02 mg/kg of body weight or 0.15-0.6 mg/m2 of body surface area per day, orally in 1-2 doses.

1. Adverse reactions that are prone to occur when taken orally in large quantities include excessive sedation, inattention, depression that may lead to suicide, and slow reaction that may occur several months after stopping the drug; drowsiness, syncope, paranoid anxiety, insomnia, dreaming, talking in sleep, headache, nervousness, Parkinson's disease (reversible after stopping the drug), fatigue, weakness, impotence, loss of libido, dysuria, breast congestion, non-puerperal lactation; 2. Less common are tarry black stools, hematemesis, abdominal cramps; angina pectoris, arrhythmias, premature ventricular contractions, bradycardia, bronchospasm, stiff and trembling fingers; 3. Occasionally, fluid retention, edema and congestive heart failure; thrombotic cytopenic purpura, excessive bleeding after prostate surgery; nasal congestion.

1. Active gastric ulcer. 2. Ulcerative colitis. 3. Depression, especially depression with suicidal tendencies.

Precautions for children: 0.005-0.02 mg/kg of body weight or 0.15-0.6 mg/m2 of body surface area is administered orally daily in 1-2 divided doses. Precautions for pregnancy and lactation: Reserpine should not be used in pregnant women unless absolutely necessary. Although this product cannot pass through the blood-brain barrier, it can pass through the placental barrier, causing respiratory depression, nasal congestion, cyanosis, anorexia, drowsiness, bradycardia, and inhibition of the newborn's clasping reflex. Reserpine can be secreted through breast milk. Precautions for the elderly: Use with caution in reduced doses according to circumstances.

When used in combination with ethanol or CNS depressants, the central nervous system inhibitory effect may be aggravated; 1 When used in combination with other antihypertensive drugs or diuretics, the antihypertensive effect may be enhanced, and dosage adjustment is required; when used in combination with beta-blockers, the latter's effect may be enhanced; 2 When used in combination with digitalis or quinidine, large doses may cause arrhythmias; 3 When used in combination with levodopa, dopamine may be depleted, leading to Parkinson's disease; 4 When used in combination with indirect adrenergic drugs such as ephedrine and amphetamine, catecholamine storage may be depleted, inhibiting the effect of adrenergic drugs; 5 When used in combination with direct adrenergic drugs such as epinephrine, isoproterenol, norepinephrine, metaraminol, and phenylephrine,

Keep in a light-proof and sealed place

0.25mg

36 months

Teyi Pharmaceutical Group Co., Ltd.

• Founded in:

  2002-05-23

• Address:

  No. 9, 11, Changxing Road, Taicheng, Taishan City

• Tax NO.:

  91440700738598678Q

• Registered Funds:

  510.788782 million yuan

• Website:

  Log in to view

• Email:

  Log in to view